Can't get a rid even at 4 year lows. Management totally inept and incompetent. Useless as they come.
Same garbage for 18 years. Same garbage. Same result in stock price. $1.72 now. Can't even hold the slightest of gains longer than a day or so. Looks like back to $1.30 again.
Why am I learning this from Yossi and not Arena IR? Where's the PR? The only thing we learn about from Arena is when free ATM options are given out to insiders. These guys are asleep at the wheel and not worthy of even a fraction of their compensation. Useless as they come.
Where do I sign up for the class action? Plenty of naked shorts in Arena 2012 to 2015. Let's get it going.
Totally sickening. The legacy of Jack Lief lives on!
This represents the most important part of the news that remains understated. I can't emphasize this enough and what it will mean to the share price in the coming weeks.
The problem is Arena never had a boat to begin with. These guys couldn't sell. Bottled water in a desert.
More important comes the recent court ruling allowing drug reps and their company to advertise and promote their drug for off label use within reason. Eisai and Arena have that ability right now to tout Belviq for the treatment of diabetes. The data is there and it is compelling. No need to run another trial. But again, they don't. Asleep at the wheel and veering off the cliff side road.
Useless Eisai. Useless CEO. Useless BoD. Truly its time to sell for whatever price. Market cannot bear another 10 years of dilution and another 10 years of lies and excuses.
I would say however long it takes a normal, respectable pharma to complete studies on CB2, double or triple the time when dealing with ARNA. Throw in a few rat studies gone bad and maybe quadruple the time.
Arena keeping true to form. 3 days left and nada. I can't think of a more incompetent management team than that found within Arena. It is out of control. Always on time with free options though. Always on time with those insider sales. Always.
Will Arena say true to form and delay results as usual? Maybe 2017? How about 2018? Come on guys! Wake up! Price per share is suffering due to your incompetence and buffoonery.
Hence the HFs who bought into GALE a few months ago, openly admitted to shorting GALE in the SEC filings from about $2 to $0.75 now covered and added to their position for the long haul. Way to round trip it folks. Now move GALE to $50 per share please.
74 thumbs down tells be a lot of new basher IDs were created in response to this single post. Too funny. Too funny.
Imagine having to log in and out of every ID just to thumbs down a post. What a life. Sad life indeed.
You must be new here. Let me fill you in. Nothing of importance will be discussed or revealed. Arena execs will stumble through 20 min presentation. 2-3 questions will be allowed. Onto the next CC. 20% drop in value. Rinse. Repeat.
Discovery will allow for identification of each and every thief and thieves' guild. I'm all in. I will contact the appropriate attorneys.
Back to the top as GALE will have a move much like JAZZ did with their BLA.
Dr. Nejadnik has more than 22 years of academic and industry experience, including twelve years with pharmaceutical and biotech companies including Jazz Pharmaceuticals, Johnson & Johnson, and Purdue Pharma. During his career, he has managed numerous clinical development teams and programs with a therapeutic focus in hematology-oncology, immunology and central nervous system diseases. In this capacity, Dr. Nejadnik has successfully developed numerous biologics and small molecules, advancing these agents towards Biologics License Application (BLA) and New Drug Application (NDA) submissions. Dr. Nejadnik joins Galena from Jazz Pharmaceuticals where he was the Executive Director, Hematology-Oncology and led the clinical team towards a recently filed NDA. Prior to Jazz, he spent seven years at Johnson & Johnson working on numerous compounds in early and late stage registrational trials in immunology and oncology.
Yeah that's what I'm talking about!
Not if they never issue PR! I have never seen a company so intent on keeping every investor in the dark. What is the problem with tooting your horn and letting investors know you are alive and well? Not Arena. Deaf, dumb, and mute.